Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial (2022)
- Authors:
- USP affiliated authors: CUNHA NETO, EDECIO - FM ; DUARTE, ALBERTO JOSE DA SILVA - FM
- Unidade: FM
- DOI: 10.1186/s12981-021-00426-z
- Subjects: HIV; IMUNOGENICIDADE DA VACINA; CÉLULAS DENDRÍTICAS; SÍNDROME DE IMUNODEFICIÊNCIA ADQUIRIDA
- Agências de fomento:
- Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [FAPESP 2013/11323-5]
- Conselho Nacional de Desenvolvimento Cientifico e TecnologicoConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) [CNPq, CNPq/DECIT ]
- ViiV Healthcare Investigator Sponsored Study
- FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
- Language: Inglês
- Imprenta:
- Source:
- Título: Aids research and therapy
- ISSN: 1742-6405
- Volume/Número/Paginação/Ano: v. 19, n. 1, article ID 2, 15p, 2022
- Status:
- Artigo publicado em periódico de acesso aberto (Gold Open Access)
- Versão do Documento:
- Versão publicada (Published version)
- Acessar versão aberta:
-
ABNT
BAPTISTA, Marcella Vassao de Almeida et al. Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial. Aids research and therapy, v. 19, n. 1, 2022Tradução . . Disponível em: https://doi.org/10.1186/s12981-021-00426-z. Acesso em: 19 abr. 2026. -
APA
Baptista, M. V. de A., Silva, L. T. da, Samer, S., Oshiro, T. M., Shytaj, I. L., Giron, L. B., et al. (2022). Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial. Aids research and therapy, 19( 1). doi:10.1186/s12981-021-00426-z -
NLM
Baptista MV de A, Silva LT da, Samer S, Oshiro TM, Shytaj IL, Giron LB, Pena NM, Cruz N, Cunha Neto E, Duarte AJ da S. Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial [Internet]. Aids research and therapy. 2022 ; 19( 1):[citado 2026 abr. 19 ] Available from: https://doi.org/10.1186/s12981-021-00426-z -
Vancouver
Baptista MV de A, Silva LT da, Samer S, Oshiro TM, Shytaj IL, Giron LB, Pena NM, Cruz N, Cunha Neto E, Duarte AJ da S. Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial [Internet]. Aids research and therapy. 2022 ; 19( 1):[citado 2026 abr. 19 ] Available from: https://doi.org/10.1186/s12981-021-00426-z - Increased expression of circulating microRNA 101-3p in type 1 diabetes patients: new insights into miRNA-regulated pathophysiological pathways for type 1 diabetes
- Chagas Disease Cardiomyopathy: Immunopathology and Genetics
- Exosomes from patients with septic shock convey miRNAs related to inflammation and cell cycle regulation: new signaling pathways in sepsis?
- Imunodeficiências secundária
- An effective CTL peptide vaccine for Ebola Zaire Based on Survivors' CD8+targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design
- Evaluation of the profile of circulating microRNAs in individuals with recent type 1 diabetes and healthy controls
- CD4+ T Cell Epitope Discovery and Rational Vaccine Design
- Linfócitos T
- Sm14 cell epitopes immunization induces protective immunity against schistosoma mansoni infection in mice
- Peptides containing T cell epitopes, derived from Sm14, but not from paramyosin, induce a Th1 type of immune response, reduction in liver pathology and partial protection against Schistosoma mansoni infection in mice
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
